BioCentury
ARTICLE | Clinical News

Apellis reports additional Phase Ib data for C3 inhibitor in PNH

April 20, 2018 5:58 PM UTC

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported data from eight evaluable patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received Soliris eculizumab in the open-label, New Zealand Phase Ib PADDOCK trial showing that once-daily 270 mg subcutaneous APL-2 reduced average lactate dehydrogenase (LDH) levels to 225 U/L by day 28 from 2,900 U/L at baseline. Additionally, seven of the eight patients had LDH levels that were below the upper limit of normal at day 28. APL-2 also increased average hemoglobin levels to 12.2 g/dL within 12 weeks from 7.9 g/dL at baseline.

Apellis previously reported data from three evaluable patients in the trial. Additional data are expected in June (see BioCentury, July 7, 2017)...

BCIQ Company Profiles

Apellis Pharmaceuticals Inc.

BCIQ Target Profiles

Complement 3 (C3)